Cargando…
Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases, such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn’s disease, and transplants, among others. Monoclonal antibodies a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151974/ http://dx.doi.org/10.1016/B978-0-323-46143-6.00025-7 |
_version_ | 1783521372805267456 |
---|---|
author | Quinteros, Daniela A. Bermúdez, José M. Ravetti, Soledad Cid, Alicia Allemandi, Daniel A. Palma, Santiago D. |
author_facet | Quinteros, Daniela A. Bermúdez, José M. Ravetti, Soledad Cid, Alicia Allemandi, Daniel A. Palma, Santiago D. |
author_sort | Quinteros, Daniela A. |
collection | PubMed |
description | Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases, such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn’s disease, and transplants, among others. Monoclonal antibodies are protein molecules made in the laboratory from hybridoma cells by recombinant DNA technology. Important advances have been made over the past decade to improve some critical points, such as safety and efficacy of the first generation of therapeutic antibodies. This type of molecules presents a significant challenge from the pharmaceutical point of view due to their characteristics, such as molecular size, stability, and solubility. In this chapter we have attempted to identify the major issues associated with therapeutic approaches, formulating drawbacks and delivering antibody drugs, particularly focused on the challenges and opportunities that these present for the future. |
format | Online Article Text |
id | pubmed-7151974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71519742020-04-13 Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery Quinteros, Daniela A. Bermúdez, José M. Ravetti, Soledad Cid, Alicia Allemandi, Daniel A. Palma, Santiago D. Nanostructures for Drug Delivery Article Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases, such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn’s disease, and transplants, among others. Monoclonal antibodies are protein molecules made in the laboratory from hybridoma cells by recombinant DNA technology. Important advances have been made over the past decade to improve some critical points, such as safety and efficacy of the first generation of therapeutic antibodies. This type of molecules presents a significant challenge from the pharmaceutical point of view due to their characteristics, such as molecular size, stability, and solubility. In this chapter we have attempted to identify the major issues associated with therapeutic approaches, formulating drawbacks and delivering antibody drugs, particularly focused on the challenges and opportunities that these present for the future. 2017 2017-03-31 /pmc/articles/PMC7151974/ http://dx.doi.org/10.1016/B978-0-323-46143-6.00025-7 Text en Copyright © 2017 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Quinteros, Daniela A. Bermúdez, José M. Ravetti, Soledad Cid, Alicia Allemandi, Daniel A. Palma, Santiago D. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery |
title | Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery |
title_full | Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery |
title_fullStr | Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery |
title_full_unstemmed | Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery |
title_short | Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery |
title_sort | therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151974/ http://dx.doi.org/10.1016/B978-0-323-46143-6.00025-7 |
work_keys_str_mv | AT quinterosdanielaa therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery AT bermudezjosem therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery AT ravettisoledad therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery AT cidalicia therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery AT allemandidaniela therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery AT palmasantiagod therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery |